|
| Status |
Public on Aug 12, 2015 |
| Title |
CXCL12/CXCR4 signaling mediates niche occupancy and tumor maintenance in T-cell leukemia |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy characterized by infiltration of the bone marrow and other sites with transformed T cell progenitors. The role of tissue microenvironments in the pathogenesis of T-ALL or any other type of acute leukemia is little understood. In delineating interactions between T-ALL cells and their environment, we initially found that T-ALL cells express high surface levels of the chemokine receptor CXCR4. Intravital imaging of an intact tibia revealed T-ALL cells in direct contact with bone marrow stromal cells producing the CXCR4 ligand, CXCL12. Genetic targeting of CXCR4 on T-ALL cells resulted in a marked reduction of leukemia burden and prolonged disease remission, and disruption of the CXCL12/CXCR4 axis using small molecule inhibitors prevented T-ALL progression in a primary xenograft model. Finally, we were able to show that CXCR4 inhibition significantly decreased expression of Myc and its target genes. Myc expression is a key regulator of T-ALL leukemia initiating cell (LIC) activity, suggesting that CXCR4 inhibition can suppress LIC activity by silencing the Myc response in T-ALL cells. Our data suggest that targeting of CXCL12/CXCR4 signaling could be a powerful new tool for combating T-ALL, a disease with no current targeted therapies.
|
| |
|
| Overall design |
Mouse T-ALL cells were treated ex vivo with Cxcr4 inhibitor AMD3100 or vehicle control. Additionally, mouse T-ALL primary tumors were isolated from control (Cxcr4+/+) or knockout (Cxcr4-/-) animals. Total RNA was extracted from samples using the RNeasy Plus Mini Kit (Qiagen). Samples were then subject to PolyA selection using oligo-dT beads (Life Technologies, Carlsbad, CA) according to the manufacturer's instructions. The resulting RNA samples were then used as input for library construction using the dUTP method as described by Parkhomchuck et al., 2009. RNA libraries were then sequenced on the Illumina HiSeq 2500 using 50bp single-end reads.
|
| |
|
| Contributor(s) |
Trimarchi T |
| Citation(s) |
26058075 |
| Submission date |
Aug 12, 2014 |
| Last update date |
May 15, 2019 |
| Contact name |
Thomas Trimarchi |
| Organization name |
NYU School of Medicine
|
| Department |
Pathology
|
| Lab |
Iannis Aifantis
|
| Street address |
550 First Ave Smilow 1307
|
| City |
New York |
| State/province |
NY |
| ZIP/Postal code |
10016 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL17021 |
Illumina HiSeq 2500 (Mus musculus) |
|
| Samples (12)
|
| GSM1477302 |
RNA-Seq analysis from AMD-treated mouse Notch1-deltaE+ T-ALL cells 1 (ex vivo-treatment) |
| GSM1477303 |
RNA-Seq analysis from AMD-treated mouse Notch1-deltaE+ T-ALL cells 2 (ex vivo-treatment) |
| GSM1477304 |
RNA-Seq analysis from AMD-treated mouse Notch1-deltaE+ T-ALL cells 3 (ex vivo-treatment) |
| GSM1477305 |
RNA-Seq analysis from vehicle-treated mouse Notch1-deltaE+ T-ALL cells 1 (ex vivo-treatment) |
| GSM1477306 |
RNA-Seq analysis from vehicle-treated mouse Notch1-deltaE+ T-ALL cells 2 (ex vivo-treatment) |
| GSM1477307 |
RNA-Seq analysis from vehicle-treated mouse Notch1-deltaE+ T-ALL cells 3 (ex vivo-treatment) |
| GSM1477308 |
RNA-Seq analysis from Cxcr4+/+ Notch1-deltaE+ mouse T-ALL cells 1 (primary tumor) |
| GSM1477309 |
RNA-Seq analysis from Cxcr4+/+ Notch1-deltaE+ mouse T-ALL cells 2 (primary tumor) |
| GSM1477310 |
RNA-Seq analysis from Cxcr4+/+ Notch1-deltaE+ mouse T-ALL cells 4 (primary tumor) |
| GSM1477311 |
RNA-Seq analysis from Cxcr4-KO Notch1-deltaE+ mouse T-ALL cells 5 (primary tumor) |
| GSM1477312 |
RNA-Seq analysis from Cxcr4-KO Notch1-deltaE+ mouse T-ALL cells 7 (primary tumor) |
| GSM1477313 |
RNA-Seq analysis from Cxcr4-KO Notch1-deltaE+ mouse T-ALL cells 8 (primary tumor) |
|
| Relations |
| BioProject |
PRJNA258103 |
| SRA |
SRP045460 |
Less...
More...